# New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

> **NCT06944145** · PHASE2 · RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 242 (estimated)

## Conditions studied

- BPH (Benign Prostatic Hyperplasia)
- Lower Urinary Track Symptoms

## Interventions

- **DRUG:** raloxifene
- **DRUG:** Finasteride

## Key facts

- **NCT ID:** NCT06944145
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2029-06-01
- **Final completion:** 2030-08-31
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06944145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06944145, "New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06944145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*